Skip to content

Comparing Ayurvedic Nasal drops (Shadbindu Ghrita) and Common Nasal Spray (Xylometazoline) for managing Allergic Rhinitis (Chronic Runny Nose)

Evaluation of comparative efficacy of Navana Nasya with Shadbindu Ghrita versus 0.1 percent Xylometazoline - Hydrochloride nasal drop in the management of Vataj Pratishyaya (Allergic Rhinitis): Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091389
Enrollment
56
Registered
2025-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

None listed

Sponsors

Dr Darpan Madhao Borkar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A patient who is willing to take part and provides signed informed consent, Patient having vataj Pratishyaya will be randomly selected, Selection is irrespective of gender, religion & socio economical class.

Exclusion criteria

Exclusion criteria: Patients having Lower respiratory tract infections, Atrophic Rhinitis, C.S.F Rhinorrhoea and any other systemic disease, recently operated patients (Nose cases), In lactating and pregnant women.

Design outcomes

Primary

MeasureTime frame
1. To assess the efficacy of navan nasya with shadbindu ghrita on TNSS and DNE in Vataj Pratishaya (Allergic rhinitis) 2. To assess the efficacy of 0.1 percent Xylometazoline Hydrochloride nasal drop on TNSS and DNE in Vataj Pratishaya (Allergic rhinitis) 3. To compare the efficacy navan nasya with shadbindu ghrita and 0.1 percent Xylometazoline Hydrochloride nasal drop on TNSS and DNE in Vataj Pratishaya (Allergic rhinitis)Timepoint: 1. Baseline (Day 0)- assessment of TNSS and DNE scores before intervention in both groups 2. Post-intervention (Day 14)- Reassessment of TNSS and DNE scores after completion of treatment in both groups.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Darpan Madhao Borkar

Mahatma Gandhi Ayurved College Hospital and Research Centre

drpramodborghare@hotmail.com9881225532

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026